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Interferon regulatory factor 4
a b s t r a c t
Primary effusion lymphoma (PEL), associated with the latent infection by KSHV, constitutively expresses
interferon-regulatory factor 4 (IRF4). We recently showed that IRF4 differentially regulates expression of
cellular interferon-stimulated genes (ISGs) and viral genes (Forero et al., 2013). Here, using inducible
IRF4 knockdown, we demonstrate that IRF4 silencing results in enhanced transcription of KSHV
replication transactivator RTA. As a result viral transcription is increased leading to virus reactivation.
Taken together, our results show that IRF4 helps maintain the balance between latency and KSHV
reactivation in PEL cells.
& 2014 Elsevier Inc. All rights reserved.
Introduction
The interferon regulatory factors (IRFs) are critical in the
regulation of innate and adaptive immune response (Tamura
et al., 2008). In contrast with other ubiquitously expressed IRFs,
IRF4 is restricted to immune cells and is required for the matura-
tion of lymphocytes (Mittrucker et al., 1997). IRF4 expression has
been linked to cellular transformation, increased proliferation, and
decreased apoptotic responses in diseases like multiple myeloma
(Iida et al., 1997), human T-lymphotropic virus 1 (HTLV-1)
infected adult T-cell leukemia (ATL) (Mamane et al., 2002;
Sharma et al., 2000), Epstein–Barr Virus (EBV) transformation of
B cells (Banerjee et al., 2013; Izumiya et al., 2009; Wang et al.,
2011; Xu et al., 2008), and primary effusion lymphoma (PEL)
(Carbone et al., 2000). Furthermore, IRF4 is involved in autoim-
mune diseases (reviewed in Xu et al. (2012)) and diet-induced
inﬂammation (Eguchi et al., 2011, 2013) indicating the need to
improve our understanding of IRF4 function in the context of
speciﬁc disease. However, the role of IRF4 in Kaposi's sarcoma-
associated herpesvirus (KSHV or human herpesvirus 8, HHV-8)
maintenance and promoting PEL is yet to be clariﬁed.
PEL is a B cell neoplasm, common amongst immunocompro-
mised individuals (Dotti et al., 1999; Jaffe, 1996). It is characterized
by a plasma cell-like phenotype and is associated with latent
infection by KSHV. In PEL cells, KSHV persists as a naked episome
with expression of a subset of viral genes (latency-associated
genes) (Cesarman et al., 1995; Dresang et al., 2011; Sarid et al.,
1998; Zhong et al., 1996). The transition from latency to lytic
replication is controlled by the KSHV replication transactivator
(RTA), which is necessary and sufﬁcient to initiate lytic gene
transcription, virion formation, and cell death. The role of RTA in
driving lytic replication has been extensively studied and factors
mediating RTA function have been well described (Guito and
Lukac, 2012). However, the signaling pathways and cellular factors
that control the transcriptional induction of RTA and their effects
on downstream gene expression remain elusive.
We have recently reported that IRF4 can directly induce a
speciﬁc subset of IFN-stimulated genes (ISGs) in a type I IFN-
independent manner, and can negatively regulate KSHV RTA
induction (Forero et al., 2013). Therefore, we hypothesized that
downregulation of IRF4 would result in the derepression of RTA
expression in PEL cells and induction of the lytic gene cascade. In
this study, we have taken a reverse genetics approach to examine
the effects of IRF4 on ISG induction and the maintenance of KSHV
latency. Our results show that IRF4 downregulation does not result
in a loss of ISG expression, but rather an increase in RTA
transcription and translation accompanied by a subsequent lytic
gene expression and increased virus production. These results
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indicate a complex interplay between RTA-responsive element
(RRE) and interferon-sensitive response element (ISRE) regulated
gene expression and establish IRF4 as a key regulator of KSHV
reactivation.
Results
Downregulation of IRF4 leads to induction of speciﬁc ISG expression
in PEL cells
The roles of IRF4 in regulating B-cell speciﬁc transcription
programs, by cooperating with various transcription factors, such
as PU.1, have been well documented (Eisenbeis et al., 1995; van der
Stoep et al., 2004). However, our previous results showed that IRF4
alone can directly bind to ISRE elements and is capable of
upregulating ISG transcription in various cell types, including
PEL cells, in the absence of PU.1 expression. This phenomenon is
further inﬂuenced by the KSHV-latency associated gene v-FLIP
(viral FLICE inhibitory protein) through its ability to activate NF-κB
(Forero et al., 2013). To investigate whether the ISG upregulation is
solely mediated through IRF4 expression, we attempted IRF4
silencing in PEL cells. Given that we were unable to obtain stable
PEL cell lines constitutively expressing IRF4-targeted shRNA, we
engineered BCBL-1 cells with doxycycline (Dox) inducible expres-
sion of either control or two separate IRF4-targeting shRNAs
(sh-IRF4, and sh-IRF4b) using strategies previously described
(Shaffer et al., 2008). Treatment of cells with Dox (100 ng/ml)
resulted in appreciable reduction in IRF4 protein (Fig. 1A) and
mRNA (Fig. 1B) in sh-IRF4 expressing cells, but not in scramble
control (sh-CTRL) or sh-IRF4b expressing cells. To verify the
speciﬁcity for IRF4 knockdown and exclude any off-target effect
by shIRF4, we analyzed the expression of IRF3 and IRF9, which
showed no detectable changes (Fig.1C). As we have previously
shown that IRF4 acts as a positive regulator of ISRE-mediated
expression of ISG60 and Cig5, we evaluated the effect of IRF4
knockdown on the expression of these genes. Unexpectedly,
transcription of ISG60 and Cig5 was increased after IRF4 depletion,
4-fold and 6-fold respectively (Fig. 1D). This was accompanied by
an increase in ISG60 protein synthesis after Dox treatment of
BCBL-1 cells (Fig. 1E).
We have reported that ectopic expression of IRF4 resulted in
the inhibition of TPA-stimulated RTA (encoded by ORF50) tran-
scription in PEL cells (Forero et al., 2013). To determine whether
depletion of IRF4 affects RTA expression in PEL cells, we examined
RTA protein synthesis in Dox (100 ng/ml) treated BCBL-1 sh-IRF4
and observed an overall increase in RTA protein expression
(Fig. 2A), and nuclear accumulation (Fig. 2B). RTA is a sequence-
speciﬁc DNA binding protein that recognizes and binds to RRE
containing viral gene promoters, as well as ISRE and ISRE-like
sequences found in the promoter regulatory regions of cellular
ISGs (Zhang et al., 2005). Indeed, ectopic expression of RTA
resulted in an almost 5-fold increase in the activity of the IFNβ
reporter relative to vector transfected cells (Fig. 2C). Furthermore,
ectopic RTA expression resulted in a 5-fold increase in the
induction of ISG60 mRNA transcription (Fig. 2D) accompanied by
an increase in ISG60 protein synthesis (Fig. 2E). It is likely then
that the unexpected ISG induction observed after IRF4 silencing is
mediated by the upregulation of RTA (Zhang et al., 2005). Taken
together, these results indicate that IRF4 is involved in maintaining
a ﬁne-tuned equilibrium between the expression levels of ISGs
and RTA in PEL cells.
IRF4 inhibits KSHV lytic gene expression
RTA plays a critical role in initiating the switch from latency to
the lytic reactivation of KSHV (Guito and Lukac, 2012; Lukac et al.,
1999, 1998). In order to deﬁne the mechanism of RTA protein
expression followed by IRF4 depletion, we treated BCBL-1 sh-CTRL
and sh-IRF4 cells with Dox for 72 h followed by stimulation with
15 ng/ml TPA for 12 h. Treatment with Dox resulted in signiﬁcantly
decreased IRF4 protein levels in BCBL-1 sh-IRF4 cells accompanied
with an increase in RTA protein synthesis (Fig. 3A, lanes 10–12).
Fig. 1. Downregulation of IRF4 results in the induction of ISG expression in PEL cells. (A) Loss of IRF4 protein expression in cells expressing an inducible IRF4 targeting
shRNA. Whole cell lysates prepared from shRNA expressing BCBL-1 cells after 72 h treatment with 100 ng/ml Dox were immunoblotted with antibodies against IRF4 and
actin. (B) Quantitative RT-PCR analysis of IRF4 mRNA levels in shRNA expressing BCBL-1 cells after 72 h treatment with 100 ng/ml dox. Samples were normalized to the
housekeeping gene, RPL32, and expressed as fold change with respect to untreated cells (value 1). (C) Speciﬁcity of IRF4 targeting by the shRNA 24 h (left) and 96 h (right)
after stimulation with Dox. Whole cell lysates prepared from shRNA expressing BCBL-1 cells after 72 h Dox treatment were immunoblotted with antibodies against IRF4,
IRF3, IRF9 and Actin. (D) Quantitative RT-PCR analysis of ISG60 and Cig5 mRNA expression in shRNA expressing BCBL-1 cells after 72 h Dox treatment. Samples were
normalized to RPL32 and expressed as fold change with respect to untreated cells (value 1). (E) Analysis of ISG60 protein induction levels in whole cell lysates prepared from
sh-IRF4 expressing BCBL-1 cells after 72 h treatment with Dox.
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Dox treatment did not affect IRF4 or RTA protein expression in sh-
CTRL cells (lanes 4 and 1). Furthermore, co-stimulation with TPA
resulted in enhanced RTA expression in sh-IRF4 cells (lanes 11 and
12) relative to Dox untreated cells (lanes 8, 9 and 5, 6) and sh-CTRL
cells. It should be noted that TPA treatment had no overall effect
on IRF4 expression in either sh-CTRL or sh-IRF4 BCBL-1 cells. The
observed increase in protein expression was due to the transcrip-
tional activation of RTA as determined by quantitative RT-PCR
Fig. 2. RTA is induced by the silencing of IRF4 and regulates ISRE mediated gene expression in PEL cells. (A) Induction of RTA protein following IRF4 knockdown. Whole cell
lysates fromBCBL-1 sh-IRF4 cells after 72 h treatment with various concentrations of Dox were immunoblotted with antibodies against IRF4, RTA and Actin. (B) Nuclear
accumulation of RTA expression follows loss of IRF4. Nuclear fractions were prepared from cell treated with Dox for 72 h. Fractions were resolved by SDS-PAGE and
immunoblotted with antibodies against IRF4, RTA, DRBP76 (nuclear marker), and Tubulin (cytoplasmic marker). (C) Effect of RTA expression on IFNβ-promoter activity.
HEK293 cells were transfected with RTA or vector control along with IFNβ125-luc and pRL-Null. Luciferase activity was measured as previously described (Forero et al., 2013).
Samples were normalized to Renilla luciferase control and expressed as fold change with respect to empty vector transfected cells (value 1). (D) Quantitative RT-PCR analysis
of ISG60 following ectopic expression of RTA in 293T cells. Samples were normalized to RPL32 and expressed as fold change with respect to empty vector transfected cells
(value 1). (E) Analysis of ISG60 protein induction following ectopic expression of RTA in 293T cells. Samples were immunbobloted with indicated antibodies.
Fig. 3. IRF4 silencing positively regulates RTA and RRE-mediated gene expression. (A) Analysis of RTA protein induction following Dox treatment and TPA stimulation in
BCBL-1 sh-CTRL and sh-IRF4 cells. Cells were stimulated with Dox for 48 h followed by an additional treatment for 24 h with 5 or 15 ng/ml TPA. Lysates were prepared after
stimulation and immunoblotted with anti-RTA, IRF4, and Actin antibodies. (B–D) qRT-PCR analysis of IRF4 and RTA mRNA levels (B); RTA target genes, ORF57, PAN and
vIL-6 (C); and LANA (D) in Dox treated BCBL-1 sh-CTRL and sh-IRF4 cells. Cells were stimulated as previously described, total RNA was harvested and subjected to qRT-PCR.
Samples were normalized to RPL32 and expressed as fold change with respect their respective untreated cells (value 1).
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analysis (qRT-PCR). Dox treatment of sh-IRF4 cells led to an
observed 3.4-fold increase in RTA mRNA compared to a 10.5-fold
increase in mRNA transcription when cells were co-stimulated
with Dox and TPA (15 ng/ml) (Fig. 3B). These results were
concordant with our previous studies demonstrating that IRF4
acts as a repressor of RTA transcription. As seen for RTA protein
synthesis, both sh-CTRL and sh-IRF4 cell lines responded equally
to treatment with TPA (Fig. 3A lanes 2, 3 and 8, 9), suggesting that
there were no inherent differences in the ability to respond to TPA
treatment.
Next, to examine the consequence of IRF4 downregulation on
direct RTA-target viral genes, we measured the induction of RTA-
responsive genes ORF57, vIL-6, and PAN mRNA (Bu et al., 2008)
following treatment of cells with Dox and TPA. Similar to the
observed RTA transcript induction, loss of IRF4 resulted in a 2–4
fold increase in basal early gene transcription of the three targets
examined relative to untreated cells (Fig. 3C). Furthermore, co-
stimulation with Dox and TPA, resulted in a signiﬁcant enhance-
ment in ORF57, PAN, and vIL-6 transcription in sh-IRF4 expressing
cells compared to that observed in co-stimulated sh-CTRL cells
(Fig. 3C). To exclude the possibility that treatment with Dox leads
to an overall increase in gene transcription, we measured the
mRNA levels of the latency-associated nuclear antigen (LANA)
following Dox and/or TPA stimulation. While treatment with TPA
resulted in a comparable decrease in LANA mRNA in both sh-CTRL
and sh-IRF4 cells, treatment with Dox showed a pattern of reduced
LANA mRNA levels in sh-IRF4 cells, but not in sh-CTRL cells relative
to non-stimulated cells. As expected, dual stimulation with Dox
and TPA resulted in a decrease in LANA mRNA in both cell lines.
(Fig. 3D) These results are consistent with previous observations
that lytic reactivation results in reduction in LANA transcription
accompanied with an induction of immediate early genes (Dillon
et al., 2013). These results indicate that IRF4 downregulation in PEL
cells is likely sufﬁcient to allow entry into the viral lytic reactiva-
tion program, rather than resulting in a non-speciﬁc activation of
viral gene expression.
IRF4 silencing results in KSHV reactivation and virus production
Bona ﬁde lytic reactivation and viral replication is accompanied
by an increase in virion structure and assembly associated gene
expression. To determine whether this occurred in BCBL-1 sh-IRF4
cells after IRF4 silencing, we measured the transcriptional induc-
tion of the genes encoding the viral glycoprotein (K8.1), ORF17, and
ORF67 by qRT-PCR, we observed higher mRNA expression of all
three genes in cells treated with Dox for 72 h, relative to non-
treated cells (Fig. 4A). Additional treatment of Dox stimulated cells
with TPA, resulted in enhanced mRNA expression of the late genes,
K8.1 and ORF17. Interestingly, while the expression of ORF67
mRNA was higher in cells treated with Dox relative to untreated
or TPA-alone treated cells, co-stimulation of cells with Dox and
TPA did not result in increases in mRNA levels compared to cells
treated with Dox alone. We then examined the induction of KSHV
viral protein expression in BCBL-1 sh-IRF4 cells stimulated with
Dox for 96 h. Cells were ﬁxed and stained using anti-KSHV sera.
We observed a signiﬁcant two fold increase in cytoplasmic stain-
ing in cells in Dox treated cells (Fig. 4B). To examine whether the
observed upregulation of KSHV lytic genes is accompanied by an
increase in viral DNA replication and virion production, we
measured KSHV DNA in the supernatant of Dox and TPA-
stimulated BCBL-1 sh-CTRL and sh-IRF4 cells. As expected, stimu-
lation of cells with TPA resulted in a signiﬁcant increase in viral
DNA detection in both sh-CTRL and sh-IRF4 cells. However, co-
stimulation with Dox and TPA did not affect viral DNA production
in sh-CTRL cells, while increased viral DNA yields were observed in
sh-IRF4 cells (Fig. 4C). Taken together, these results indicate that
loss of IRF4 results in the induction of lytic gene expression in a
portion of BCBL-1 sh-IRF4 cells and leads to an increased sensi-
tivity to reactivation stimuli.
Discussion
One important feature in the life cycle of herpesviruses is their
ability to establish life-long latent infections, which acts as a
mechanism for immune evasion and contributes to the pathogen-
esis of viral related malignancies. To understand the events that
determine whether the virus will establish latency or undergo lytic
replication requires an understanding the cellular signals that
shape these outcomes. To date, studies have focused on under-
standing various stimuli for KSHV reactivation like chemical
treatment of PEL cells with phorbol esters (Moore et al., 1996b)
and histone deacetylase inhibitors (Lu et al., 2003), inhibition of
calcium signaling (Zoeteweij et al., 2001), hypoxia (Davis et al.,
2001), viral infection (Gregory et al., 2009), and BCR stimulation
(Kati et al., 2013). These studies have been instrumental
in identifying various kinases (such as PI3K (Kati et al., 2013),
Pim-1 and Pim-3 (Cheng et al., 2009), ERK1/2 (Cohen et al., 2006),
and PKC (Deutsch et al., 2004) and transcription factors (Sp1 (Ye et
al., 2005), C/EBP (Wang et al., 2003), CBF1/CSL (Scholz et al., 2013;
Wang and Yuan, 2007), Oct-1 (Carroll et al., 2007), HMGB-1
(Harrison and Whitehouse, 2008), and XBP-1 (Kati et al., 2013;
Lai, Farrell, and Kellam, 2011)) that promote RTA induction and
RTA-mediated viral gene expression. Similarly, several factors
which antagonize RTA induction and RTA-mediated gene expres-
sion have also been identiﬁed. These include Tousled-like kinases
(TLKs) (Dillon et al., 2013) and transcriptional repressors, K-RBP
(Yang and Wood, 2007) and Hey1 (Gould et al., 2009).
Recently, we have identiﬁed IRF4 as a regulator of ISRE and RRE
mediated gene expression (Forero et al., 2013). The present study
extends our previous ﬁndings and conﬁrms IRF4 as a negative
regulator of RTA expression and function, contributing to the
maintenance of latency in PEL cells. Previous reports have shown
that latently infected PEL cells display varying levels of IRF4
expression (Arguello et al., 2003; Carbone et al., 2000; Forero et
al., 2013). BCP-1 cells, which express lower IRF4 expression, show
higher levels of vIL-6 mRNA accompanied by increased protein
production (Moore et al., 1996a); pointing towards a possible
negative regulation of lytic gene expression by IRF4. Other studies
have shown that another interferon regulatory factor, IRF7, is also
an inhibitor of KSHV lytic gene expression (Wang et al., 2005).
Furthermore, IRF2 has also been shown to control latency of a
murine gammaherpesvirus closely related to KSHV, Murine her-
pesvirus 68 (Mandal et al., 2011). Together, these studies highlight
the contributions of IRF proteins in the balanced regulation
between the gammaherpesvirus latent and lytic replication
phases, which is crucial for efﬁcient viral spread and persistence
and contribute to pathogenesis and transformation.
Besides PEL, KSHV infection is associated with another B cell
malignancy localized to the mantle zone of lymph nodes and the
spleen, multicentric Castleman's disease (MCD). Unlike PEL, MCD is
polyclonal in nature and is comprised of both KSHVve and
KSHVþve cells. Hassman et al. demonstrated that infection of
tonsillar B cells with KSHV resulted in the establishment of latency
nearly exclusively in IgMλ B cells and promoted their proliferation
and differentiation (Hassman et al., 2011). Given the requirement of
IRF4 expression for secondary receptor editing (Pathak et al., 2008),
and its association with the plasma cell phenotype, it is possible that
the initial establishment of KSHV latency in B cells is a result of KSHV
infection of cells with high levels of IRF4 expression. This is followed
by inhibition of RTA expression by IRF4 resulting in KSHV latency and
tumorigenesis (Carbone et al., 2000). Further studies would shed
A. Forero et al. / Virology 458-459 (2014) 4–10 7
new light on the role of IRF4 in restricting KSHV lytic replication after
primary infection and illustrate the importance of IRF4 in the genesis
of KHSV-related B cell malignancies PEL and MCD.
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Materials and methods
Cells, reagents, and plasmids
HEK293 and BCBL-1-derived cells were cultured as previously
described (Forero et al., 2013). Doxycycline (Dox; Clontech) sti-
mulations were done for 24–96 h at varying doses (as indicated)
and 12-O-tetradecanoylphorbol-13-acetate (TPA; Sigma Aldrich)
stimulations were done with 5 or 15 ng/ml (as indicated) for 12 h.
Primary antibodies used in this study: anti-IRF4 (Cell Signaling),
anti-Actin and anti-Tubulin (Santa Cruz), anti- ISG60 and anti-
DRBP76 (Sarkar et al., 2004), and anti-ORF50 (Toptan et al., 2013).
pcDNA/ORF50 and reporter plasmids pGL3-IFNβ125 ﬁreﬂy lucifer-
ase and pRL null have been previously described (Forero et al.,
2013). Retroviral packaging plasmids pHIT60 expressing MoMuLV
Gag and Pol and the ecotropic envelope-expressing plasmid pHIT/
EA63n, along with the doxycycline-inducible non-targeting
shRNA (shCTRL), IRF4 targeting shRNA (shIRF4 and shIRF4b)
retroviral vectors were obtained from Dr. Louis Staudt (NIH) and
have been previously described (Ngo et al., 2006; Shaffer et al.,
2008).
Generation of cells with inducible IRF4 knockdown
BCBL-1 cells were engineered to stably express the ecotropic
retroviral receptor and the bacterial tetracycline repressor (TETR)
as previously described (Ngo et al., 2006). Cells were then infected
with retroviruses expressing doxycycline-inducible short-hairpins
targeting IRF4 and a scramble control and placed under puromycin
Fig. 4. Loss of IRF4 results in a robust induction of KSHV lytic gene expression and viral reactivation. (A) qRT-PCR analysis of late genes K8.1, ORF17, and ORF67 in Dox treated
BCBL-1 sh-CTRL and sh-IRF4 cells. Cells were stimulated as previously described, total RNA was harvested and subjected to qRT-PCR. Samples were normalized to RPL32 and
expressed as fold change with respect to their respective untreated cells (value 1). (B) BCBL-1 sh-IRF4 stimulated with Dox for 96 h. Following stimulation, cells were ﬁxed,
stained with KSHV positive human sera (green), nuclei were stained with DAPI (blue), and samples imaged by confocal microscopy. Sample immunoﬂuorescence image is
shown (left). Quantiﬁcation of KSHV reactivation (right). Cells positive for KSHV reactivation were manually counted from a series of 40 ﬁelds. (C) KSHV virion production
following IRF4 silencing. BCBL-1 sh-CTRL and sh-IRF4 cells were stimulated with Dox for 72 h followed by stimulation with TPA (15 ng/ml) or Dox and TPA for an additional
72 h. KSHV DNA released into the supernatant was measured by probed-based qPCR. Results are expressed as fold change with respect to their respective untreated cells
(value 1).
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selection (1 ug/ml) for 7 days. Antibiotic resistant cells were then
used for further assays.
Quantitative PCR analysis of cellular and KSHV gene expression
BCBL-1/sh-CTRL and BCBL-1/sh-IRF4 cells were stimulated with
100 ng/ml Dox for 72 h and/or TPA at the indicated doses for an
additional 12 h. Total RNA was extracted and real-time PCR was
performed as previously described (Forero et al., 2013). Primers
used for KSHV target gene ampliﬁcation can be found in
Supplementary Table 1. Expression of mRNA was normalized to
housekeeping gene RPL32 and expressed as fold change with
respect to their respective mock treated cells (value 1).
Immunoﬂuorescence microscopy
BCBL-1/sh-IRF4 cells were treated with 100 ng/ml Dox for 96 h.
Cells were ﬁxed with 4% PFA and permeabilized with 0.1% Triton-X
in PBS. Cells were seeded onto poly-L-Lysine coated slides (Fisher
Scientiﬁc) and left to air dry. After blocking with 10% goat serum
for 1 h at 37 1C, cells were incubated with KSHV positive human
sera from an individual with PEL for 1 h at 37 1C, washed and
incubated with a mouse monoclonal antibody directed against
human IgG (Sigma) 1 h at 37 1C. Finally, cells were incubated with
mouse anti IgG–FITC-conjugated secondary antibody (Santa Cruz)
for 1 h at 37 1C. Slides were ﬁxed and mounted with Vectashield
containing DAPI. Images were captured with a FV1000 Olympus
confocal laser scanning microscope. A total of 36 images per
condition taken from triplicate experiments were analyzed for
quantiﬁcation of reactivating cells.
KSHV reactivation assay
BCBL-l sh-CTRL or sh-IRF4 (2106 cells) were stimulated with
Dox (100 ng/ml) for 72 h followed by stimulation with TPA (15 ng/
ml) and Dox (100 ng/ml) or vehicle control for an additional 72 h
(as indicated). Supernatants were clariﬁed by centrifugation at 1200
RPM for 10 min followed by ultracentrifugation at 12,000 rpm for
3 h to isolate KSHV virions. Pellets were resuspended in 500 ml
1PBS and DNAse I (Ambion) treated for 30 min at 37 1C to remove
any intracellular KSHV DNA. DNA was then extracted with phenol–
chloroform and resuspended in 100 ml nuclease free water. KSHV
DNA was quantiﬁed by probe-based quantitative PCR with Ampli-
Taq Gold 360 Master Mix (Invitrogen) according to manufacturer's
guidelines using primers and a probe targeting the K8 gene
(Forward primer 50–GTCTCTTGGACAAGCTCGCTGTT-30, Reverse pri-
mer 50–AGTGAGCATGGCAGATGTTCGT-30; and FAM probe 50–CG
GTCTGTGAAACGGTCATTGACCTTAC-30 (as described in Qu et al.
(2011)).
Statistical analysis
Data were analyzed using two-tailed paired Student's t-test.
Values were considered signiﬁcant at po0.05.
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